Subscribe
Earnings
3 min read

PetMeds halves its ad spend as sales keep falling

PetMeds' fiscal second-quarter net sales fell 19.4% to $35.8M while advertising spending dropped by more than half, and the net loss narrowed to $6.4M. The release gives no guidance.

Published on
November 11, 2026
PetMeds halves its ad spend as sales keep falling

PetMeds cut its advertising spending by more than half in its fiscal second quarter, and net sales still fell 19.4%, close to the 19.9% decline in the first quarter. PetMed Express, which trades as PETS and owns PetCareRx, reported net sales of $35.8M for the three months ended September 30th, down from $44.4M a year earlier. The net loss narrowed to $6.4M, or $0.31 per diluted share, from $8.5M, or $0.41.

Sales fell 19.4% and the company cites prescriptions

Gross profit fell to $9.8M from $12.4M, and gross margin slipped to 27.4% from 28.0%, by our math. The company said the decline in net sales was "primarily driven by a decline in prescription medication sales and higher consumer promotional usage." General and administrative expenses fell to $12.0M from $14.2M, and advertising fell to $2.1M from $4.3M.

Adjusted EBITDA loss widened to $3.6M from $2.3M. Cash and equivalents were $11.4M on September 30th, down from $21.4M on March 31st. For the six months, net sales were $76.8M against $95.5M, and the net loss was $12.6M against $42.7M. The prior-year six months included a $27.3M impairment of goodwill and intangibles. The release contains no guidance or outlook.

Jeff Willard, the chief executive and president, said "this quarter we cut our cost to acquire a new customer by 32% from a year ago." He also said "We have stabilized the operations of the business." Willard took over on September 28th, two days before the quarter closed, so most of the quarter fell under the previous leadership. The release gives no customer counts.

Cheaper customer acquisition has not stopped the revenue slide

By our math, advertising fell to 5.8% of net sales from 9.8%. In the first quarter, advertising fell about 30% and sales fell 19.9%. In the second, advertising fell 52% and sales fell 19.4%. Our read is that advertising is not what is driving the sales decline, though two quarters is a short record. The company's own explanation is prescription sales and promotions.

Cost cuts produced the smaller loss. General and administrative expenses and advertising together fell $4.5M, while gross profit fell $2.6M, by our math. Adjusted EBITDA, which the company reports separately, moved the other way.

Cash fell $10.0M, or 47%, from March 31st, by our math. The first quarter used $8.3M and the second used about $1.7M, since the first-quarter balance was $13.1M. The figures do not show whether the slower pace reflects timing or a lasting change.

Watch the sale-leaseback close and third-quarter advertising

The release does not mention the pharmacy programs with Pet Supermarket or Rural King, so there is still no revenue figure for either. We covered the Pet Supermarket program when it was announced. The release also does not mention the proposal of $3 per share from SilverCape Investments.

The sale-leaseback of the Delray Beach headquarters and distribution center is the next hard number. The company's July 23rd announcement said the $37M deal was expected to close within 120 days, which ends near November 20th by our math. The release does not mention it. By our math, the $37M price is more than three times the September 30th cash balance.

The next test is whether the marketing steps the release lists, including a brand repositioning, bring sales back without a rise in advertising spend.

Source: PetMeds via GlobeNewswire

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
CompanAIn names animal health veteran Brük Herbst COO
People
4 min read

CompanAIn names animal health veteran Brük Herbst COO

CompanAIn, a Charleston company building an AI-native health platform for dogs, cats and horses, named Brük Herbst chief operating officer. Herbst, a former IDEXX, Covetrus and Zomedica executive, will lead its move from platform validation to commercial scale.

Read article
Read article
Pivotal Group buys animal health manufacturer Precision Science
Funding & M&A
3 min read

Pivotal Group buys animal health manufacturer Precision Science

Pivotal Group, a Phoenix investment firm, has acquired Precision Science, a Phoenix animal health contract manufacturer founded in 1989. Pivotal said a 130,000-square-foot North Phoenix plant, two-thirds complete, will add three manufacturing lines and expand into liquids.

Read article
Read article
Loyal taps Argenta for early development of its LOY-003 dog drug
Strategy
3 min

Loyal taps Argenta for early development of its LOY-003 dog drug

Loyal has brought in animal health contract manufacturer Argenta to support early-stage development of LOY-003, its daily pill for large and giant-breed dogs.

Read article
View all articles